Additionally, inverse associations were found in those who wee diagnosed with ER+/PR+ malignancy and those who receiving anastrozole as endocrine therapy.
They determined that, due to inconsistent refills, 19 percent of the women (211) had access to the drug less than 80 percent of the 12-month period after they first filled an anastrozole prescription.